Literature DB >> 8765144

Ataxia telangiectasia heterozygotes and patients display increased fluidity and decrease in contents of sulfhydryl groups in red blood cell membranes.

M Rybczyńska1, A L Pawlak, E Sikorska, R Ignatowicz.   

Abstract

In red blood cell membranes of ataxia telangiectasia mutated (ATM) homozygotes and heterozygotes, decreased values of the corrected fluorescence anisotropy and the anisotropy parameter were found, indicating increased fluidity and decreased microviscosity, respectively. These changes in membranes were accompanied by a decrease in SH-groups and an increase in malondialdehyde (MDA) contents. The content of MDA both in homozygotes and in heterozygotes exceeded roughly threefold the respective control values. Decreased content of GSH in red blood cells was found only in ATM homozygotes. The change most specific for the ATM gene appears to be the increase in fluidity, since only this parameter displays the proportionally greater changes in ATM homozygotes compared to ATM heterozygotes. The observations presented here may indicate that the ATM gene is expressed in precursors of red blood cells and deficiency of normal AT gene function may produce the changes which persist in circulating cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765144     DOI: 10.1016/0005-2760(96)00067-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  1 in total

1.  Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial.

Authors:  Luciana Chessa; Vincenzo Leuzzi; Alessandro Plebani; Annarosa Soresina; Roberto Micheli; Daniela D'Agnano; Tullia Venturi; Anna Molinaro; Elisa Fazzi; Mirella Marini; Pierino Ferremi Leali; Isabella Quinti; Filomena Monica Cavaliere; Gabriella Girelli; Maria Cristina Pietrogrande; Andrea Finocchi; Stefano Tabolli; Damiano Abeni; Mauro Magnani
Journal:  Orphanet J Rare Dis       Date:  2014-01-09       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.